Ambra V. Gualeni
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis.
Journal: Frontiers in immunology
Published: September 17, 2018
Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients.
Journal: Expert review of molecular diagnostics
Published: February 13, 2018
Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
Journal: Endocrine-related cancer
Published: December 27, 2017
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.
Journal: The Journal of clinical investigation
Published: October 12, 2017
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 23, 2017
In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating.
Journal: Human pathology
Published: July 12, 2017
Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis.
Journal: Expert review of hematology
Published: May 05, 2017
Epstein-Barr virus associated lymphomas in people with HIV.
Journal: Current opinion in HIV and AIDS
Published: October 19, 2016
microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response.
Journal: Genes
Published: October 09, 2016
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.
Journal: Oncotarget
Published: April 05, 2016
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
Journal: Cancer discovery
Published: March 10, 2016
Last Updated: 09/26/2026